Novanta Inc (NASDAQ:NOVT) Director Stephen W. Bershad sold 500,000 shares of the stock in a transaction that occurred on Thursday, November 15th. The shares were sold at an average price of $68.15, for a total value of $34,075,000.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Shares of Novanta stock opened at $64.47 on Thursday. Novanta Inc has a 12 month low of $43.65 and a 12 month high of $78.85. The company has a market cap of $2.42 billion, a P/E ratio of 40.29 and a beta of 1.72. The company has a debt-to-equity ratio of 0.69, a current ratio of 2.89 and a quick ratio of 1.97.

Novanta (NASDAQ:NOVT) last announced its quarterly earnings results on Tuesday, November 6th. The technology company reported $0.61 EPS for the quarter, beating analysts’ consensus estimates of $0.52 by $0.09. Novanta had a return on equity of 18.95% and a net margin of 6.18%. The company had revenue of $160.79 million during the quarter, compared to analyst estimates of $154.43 million. During the same period in the prior year, the company earned $0.45 earnings per share. The firm’s revenue was up 9.9% on a year-over-year basis. Research analysts predict that Novanta Inc will post 2.06 earnings per share for the current year.

A number of hedge funds have recently modified their holdings of the business. Sapphire Star Partners LP raised its position in Novanta by 4.3% during the third quarter. Sapphire Star Partners LP now owns 16,349 shares of the technology company’s stock valued at $1,118,000 after purchasing an additional 667 shares during the period. Yorktown Management & Research Co Inc raised its position in Novanta by 9.7% during the third quarter. Yorktown Management & Research Co Inc now owns 9,712 shares of the technology company’s stock valued at $664,000 after purchasing an additional 861 shares during the period. Xact Kapitalforvaltning AB raised its position in Novanta by 17.1% during the third quarter. Xact Kapitalforvaltning AB now owns 6,151 shares of the technology company’s stock valued at $421,000 after purchasing an additional 900 shares during the period. Metropolitan Life Insurance Co. NY raised its holdings in shares of Novanta by 9.8% in the second quarter. Metropolitan Life Insurance Co. NY now owns 10,527 shares of the technology company’s stock worth $656,000 after buying an additional 943 shares during the period. Finally, Envestnet Asset Management Inc. raised its holdings in shares of Novanta by 58.7% in the second quarter. Envestnet Asset Management Inc. now owns 2,571 shares of the technology company’s stock worth $160,000 after buying an additional 951 shares during the period. Institutional investors and hedge funds own 86.89% of the company’s stock.

A number of equities analysts recently commented on NOVT shares. BidaskClub lowered Novanta from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, August 1st. Zacks Investment Research raised Novanta from a “hold” rating to a “buy” rating and set a $74.00 price target for the company in a research note on Saturday, August 11th. Finally, ValuEngine lowered Novanta from a “buy” rating to a “hold” rating in a research note on Saturday, October 6th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Novanta has a consensus rating of “Buy” and a consensus target price of $67.00.

TRADEMARK VIOLATION WARNING: This article was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.dailypolitical.com/2018/11/22/insider-selling-novanta-inc-novt-director-sells-34075000-00-in-stock.html.

Novanta Company Profile

Novanta Inc, together with its subsidiaries, designs, manufactures, markets, and sells photonics, vision, and precision motion components and sub-systems to original equipment manufacturers in the medical and industrial markets worldwide. The company's Photonics segment offers photonics-based solutions, including laser scanning and laser beam delivery, CO2 laser, continuous wave and ultrafast laser, and optical light engine products for photonics-based applications, such as industrial material processing, metrology, medical and life science imaging, DNA sequencing, and medical laser procedures.

Featured Story: How to Profit and Limit Losses With Stop Orders

Insider Buying and Selling by Quarter for Novanta (NASDAQ:NOVT)

Receive News & Ratings for Novanta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novanta and related companies with MarketBeat.com's FREE daily email newsletter.